synovial sarcoma

Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers

Adaptimmune and TCR2 Therapeutics have complementary technologies and an aligned strategy of developing cell therapies for solid tumors, but this marriage is preceded by divorce. Before consummating the TCR2 deal, Adaptimmune ended an alliance with a larger pharmaceutical company.

By Frank Vinluan

BioPharma

Adaptimmune’s ASCO data for cell therapy in sarcoma spark optimism about Phase II study potential

One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies' potential outside of the blood cancer space.

By Alaric DeArment